Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000352400

Medchemexpress LLC Taselisib | 1282512-48-4 | 99.8% | 460.53 | 200 MG
SDP

Catalog No. 5000352400
Encompass_Preferred

Taselisib (GDC-0032) is a potent PI3K inhibitor that selectively targets PIK3CA mutations, exhibiting Kis of 0.12 nM for PI3Kδ, 0.29 nM for PI3Kα, 0.97 nM for PI3Kγ, and 9.1 nM for PI3Kβ. It is provided as a white to off-white solid. Taselisib inhibits AKT/mTOR signaling in PIK3CA mutant cell lines and has been shown to enhance radiation-induced apoptosis and inhibit growth in head and neck cancer cell lines. In vivo studies demonstrate that it potently impairs PI3K signaling and enhances the efficacy of fractionated radiotherapy in xenograft models.

  • Potent PI3K inhibitor targeting PIK3CA mutations.
  • Inhibits AKT/mTOR signaling in PIK3CA mutant cell lines.
  • Enhances radiation-induced apoptosis.
  • Inhibits growth in head and neck cancer cell lines.
  • Impairs PI3K signaling in vivo.
  • Enhances efficacy of fractionated radiotherapy in animal models.

Catalog No. 50-003-52400 Supplier Medchemexpress LLC Supplier No. HY13898200MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Taselisib (GDC-0032) is a potent PI3K inhibitor that selectively targets PIK3CA mutations, exhibiting Kis of 0.12 nM for PI3Kδ, 0.29 nM for PI3Kα, 0.97 nM for PI3Kγ, and 9.1 nM for PI3Kβ. It is provided as a white to off-white solid. Taselisib inhibits AKT/mTOR signaling in PIK3CA mutant cell lines and has been shown to enhance radiation-induced apoptosis and inhibit growth in head and neck cancer cell lines. In vivo studies demonstrate that it potently impairs PI3K signaling and enhances the efficacy of fractionated radiotherapy in xenograft models.

  • Potent PI3K inhibitor targeting PIK3CA mutations.
  • Inhibits AKT/mTOR signaling in PIK3CA mutant cell lines.
  • Enhances radiation-induced apoptosis.
  • Inhibits growth in head and neck cancer cell lines.
  • Impairs PI3K signaling in vivo.
  • Enhances efficacy of fractionated radiotherapy in animal models.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.